Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events.

Background: Dupilumab has been added to National Cancer Comprehensive Network (NCCN) guidelines as a therapeutic strategy for managing certain cutaneous immune-related adverse events (cirAEs) from immune checkpoint inhibitor (ICI) therapy. However, little is known about the implications of dupilumab for cancer outcomes in this population. In this multi-institutional study, we evaluate the impact of dupilumab treatment on survival among ICI recipients.

Correction: Harper et al. Alberta Childhood Cancer Survivorship Research Program. 2023, , 3932.

[...

Fertility-Related Concerns in Long-Term Survivors of Childhood Cancer: A Canadian Cohort Study.

Survivors of childhood cancer face reduced fertility, which can be a significant cause for concern. Our study aimed to assess the prevalence of fertility-related concerns and identify associated factors. Self-report data were collected with the Long-Term Survivor Questionnaire at the Alberta Children's Hospital's Long-Term Survivor Clinic (LTSC) between January 2021 and September 2023.

Wastewater-based estimation of temporal variation in shedding amount of influenza A virus and clinically identified cases using the PRESENS model.

Wastewater-based estimation of infectious disease prevalence in real-time assists public health authorities in developing effective responses to current outbreaks. However, wastewater-based estimation for IAV remains poorly demonstrated, partially because of a lack of knowledge about temporal variation in shedding amount of an IAV-infected person. In this study, we applied two mathematical models to previously collected wastewater and clinical data from four U.

Glucagon-like Peptide-1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors.

Background: Immune checkpoint inhibitors (ICIs) are associated with an increased risk of major adverse cardiovascular events (MACE). Glucagon-like peptide-1 agonists (GLP1a), initially developed for type 2 diabetes mellitus (T2DM), have shown promising results in reducing cardiovascular events. We aimed to investigate the effect of GLP1a on cardiovascular events in patients receiving ICIs.